Key clinical point: The risk of serious adverse events in patients on certolizumab varies considerably by indication, the concomitant use of systemic corticosteroids, and obesity.
Major finding: The serious infection rate in patients on certolizumab was 1.5 per 100 patient-years in those with psoriasis, 5.97 in those with Crohn’s disease, and 3.44 cases per 100 patient-years among rheumatoid arthritis patients.
Study details: This was a retrospective analysis of all serious adverse events occurring in the 11,317 certolizumab-treated patients in the 49 clinical trials encompassing all indications for the biologic.
Disclosures: The presenter reported serving as a consultant to and receiving research funding from UCB, the study sponsor, as well as more than two dozen other pharmaceutical companies.
Blauvelt A. EADV 2019, Abstract FC04.06.